Advanced Biomed Inc. - Common Stock
Advanced Biomed Inc. - Common Stock
Aktie · US00752P1049 · ADVB (XNAS)
Übersicht Finanzkennzahlen
0,96 USD
-1,23 % -0,01 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
12.06.2025 20:24

Aktuelle Kurse von Advanced Biomed Inc. - Common Stock

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
ADVB
USD
12.06.2025 20:24
0,96 USD
0,95 USD
+0,85 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 2,25 % 5,17 % -74,38 % -74,38 % -74,38 % -74,38 %

Perfil de la empresa para Advanced Biomed Inc. - Common Stock Acción

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Datos de la empresa

Nombre Advanced Biomed Inc. - Common Stock
Empresa Advanced Biomed Inc. Common Stock
Símbolo ADVB
Sitio web https://www.advanbiomed.com
Mercado principal XNAS NASDAQ
ISIN US00752P1049
Tipo de valor Acción
Sector Healthcare
Industria Medical - Diagnostics & Research
CEO Dr. Yi Lu Ph.D.
Capitalización de mercado 42 Mio
País Estados Unidos de América
Moneda USD
Empleados 0,0 T
Dirección 122 East 42nd Street, 10168 New York
Fecha de OPV 2025-03-06

Símbolos de cotización

Nombre Símbolo
NASDAQ ADVB

Otras acciones

Los inversores que tienen Advanced Biomed Inc. - Common Stock también tienen las siguientes acciones en su cartera:
DT.PFBR.BANK PF.R.15327
DT.PFBR.BANK PF.R.15327 Bono
PIEDMONT OFFICE REALTY TRUST INC - CLASS A
PIEDMONT OFFICE REALTY TRUST INC - CLASS A Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025